Insmed Incorporated (INSM) Director Melvin Md Sharoky Acquires 11,205 Shares

Insmed Incorporated (NASDAQ:INSM) Director Melvin Md Sharoky bought 11,205 shares of the company’s stock in a transaction that occurred on Friday, November 9th. The stock was purchased at an average price of $16.34 per share, for a total transaction of $183,089.70. Following the acquisition, the director now directly owns 231,794 shares in the company, valued at $3,787,513.96. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Melvin Md Sharoky also recently made the following trade(s):

  • On Monday, November 12th, Melvin Md Sharoky bought 8,795 shares of Insmed stock. The stock was purchased at an average price of $15.59 per share, for a total transaction of $137,114.05.

Shares of NASDAQ:INSM traded down $0.08 on Tuesday, hitting $15.97. 46,378 shares of the company were exchanged, compared to its average volume of 895,333. Insmed Incorporated has a one year low of $13.85 and a one year high of $33.94. The company has a debt-to-equity ratio of 1.07, a quick ratio of 10.06 and a current ratio of 10.06. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -5.63 and a beta of 1.73.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.08). Equities analysts predict that Insmed Incorporated will post -4.11 EPS for the current year.

Several research analysts recently commented on the stock. Morgan Stanley lifted their target price on shares of Insmed from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, August 6th. ValuEngine downgraded shares of Insmed from a “buy” rating to a “hold” rating in a report on Tuesday, October 2nd. Goldman Sachs Group assumed coverage on shares of Insmed in a report on Monday, July 23rd. They set a “neutral” rating and a $32.00 price objective on the stock. BidaskClub downgraded shares of Insmed from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 19th. Finally, Credit Suisse Group boosted their price objective on shares of Insmed from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, October 1st. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Insmed has a consensus rating of “Buy” and a consensus target price of $35.50.

Several large investors have recently bought and sold shares of the company. Bellevue Group AG increased its stake in Insmed by 33.5% in the third quarter. Bellevue Group AG now owns 566,301 shares of the biopharmaceutical company’s stock valued at $11,451,000 after acquiring an additional 142,250 shares during the period. Dimensional Fund Advisors LP bought a new stake in Insmed in the third quarter valued at about $4,396,000. Altshuler Shaham Ltd bought a new stake in Insmed in the third quarter valued at about $1,082,000. FMR LLC increased its stake in Insmed by 0.5% in the third quarter. FMR LLC now owns 11,556,128 shares of the biopharmaceutical company’s stock valued at $233,666,000 after acquiring an additional 62,658 shares during the period. Finally, Asymmetry Capital Management L.P. increased its stake in Insmed by 81.2% in the third quarter. Asymmetry Capital Management L.P. now owns 360,182 shares of the biopharmaceutical company’s stock valued at $7,283,000 after acquiring an additional 161,381 shares during the period.

COPYRIGHT VIOLATION WARNING: This news story was first reported by WKRB News and is owned by of WKRB News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/11/13/insmed-incorporated-insm-director-melvin-md-sharoky-acquires-11205-shares.html.

About Insmed

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.

Recommended Story: What is a Swap?

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply